Trevi Therapeutics Prices $150 Million Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TRVI?
Source: Newsfilter
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Arrangement: The offering is managed by top-tier firms including Morgan Stanley, Leerink Partners, Cantor, and Stifel, with Oppenheimer & Co. as the lead manager, indicating robust institutional support for the financing effort.
- Additional Share Option: Trevi has granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, a strategy that could further enhance the company's capital-raising capabilities and meet market demand.
- Expected Closing Date: The offering is anticipated to close around April 20, 2026, subject to customary closing conditions, and if successful, will provide critical funding for the company's ongoing research and market expansion efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRVI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRVI
Wall Street analysts forecast TRVI stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.270
Low
16.00
Averages
21.22
High
25.00
Current: 14.270
Low
16.00
Averages
21.22
High
25.00
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TREVI THERAPEUTICS INC ANNOUNCES $150 MILLION GROSS PROCEEDS FROM 11.6 MILLION SHARE OFFERING PRICED AT $13.00 PER SHARE
- Company Overview: Trevi Therapeutics is offering 11.6 million shares at a price of $13.00 per share.
- Financial Goals: The offering aims to raise gross proceeds of $150 million.
See More
TREVI THERAPEUTICS REVEALS PRICING FOR $150 MILLION UNDERWRITTEN COMMON STOCK OFFERING
- Company Announcement: Trevi Therapeutics has announced a pricing of $150 million for its underwritten offering of common stock.
- Financial Strategy: The offering aims to raise capital to support the company's ongoing operations and development initiatives.
See More
Trevi Therapeutics Prices $150 Million Public Offering of Common Stock
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Arrangement: The offering is managed by top-tier firms including Morgan Stanley, Leerink Partners, Cantor, and Stifel, with Oppenheimer & Co. as the lead manager, indicating robust institutional support for the financing effort.
- Additional Share Option: Trevi has granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, a strategy that could further enhance the company's capital-raising capabilities and meet market demand.
- Expected Closing Date: The offering is anticipated to close around April 20, 2026, subject to customary closing conditions, and if successful, will provide critical funding for the company's ongoing research and market expansion efforts.
See More
Trevi Therapeutics Raises $150 Million in Public Offering
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market confidence in its investigational therapy Haduvio™.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering, indicating robust professional support in capital markets and enhancing investor trust in the company's future prospects.
- Additional Share Option: Trevi granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, providing flexibility that could further enhance the company's financing capabilities to support R&D and market expansion.
- Regulatory Compliance: The offering is conducted under a shelf registration statement on Form S-3 filed on November 13, 2025, ensuring compliance and providing transparent disclosures to investors, thereby strengthening market confidence in the company's governance.
See More
Trevi Therapeutics Announces $150M Public Offering
- Funding Size: Trevi Therapeutics has announced a public offering of $150 million aimed at supporting the development of Haduvio, its investigational therapy for chronic cough, indicating the company's proactive approach in drug development.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in shares, a strategy that not only provides extra financial flexibility but may also enhance market demand for its stock.
- R&D Focus: The proceeds will primarily support the development of Haduvio (oral nalbuphine ER), targeting chronic cough symptoms, which highlights Trevi Therapeutics' commitment to addressing this unmet medical need and potentially generating new revenue streams.
- Clinical Trial Plans: Trevi Therapeutics is set to conduct two pivotal Phase III trials focused on IPF-related chronic cough, having achieved alignment with the FDA, which lays a solid foundation for the company's future market access.
See More
Trevi Therapeutics to Participate in Multiple Healthcare Conferences
- Management Participation: Trevi Therapeutics' senior management will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, showcasing their research progress on chronic cough, which is expected to enhance investor interest in the company's R&D efforts.
- Key Event Schedule: The company will present its Haduvio™ therapy at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026, aiming to attract potential investors and strengthen market awareness.
- Investor Day Activities: Trevi plans to hold an Investor and Analyst Day on May 7, 2026, in New York, inviting key opinion leaders in chronic cough to enhance engagement and trust with investors.
- Chronic Cough Market Demand: Trevi's Haduvio™ addresses the urgent needs of approximately 150,000 U.S. patients with IPF and 230,000 with non-IPF ILD, highlighting its strategic significance in a market with high unmet medical needs.
See More
TREVI THERAPEUTICS INC ANNOUNCES $150 MILLION GROSS PROCEEDS FROM 11.6 MILLION SHARE OFFERING PRICED AT $13.00 PER SHARE
- Company Overview: Trevi Therapeutics is offering 11.6 million shares at a price of $13.00 per share.
- Financial Goals: The offering aims to raise gross proceeds of $150 million.
See More
TREVI THERAPEUTICS REVEALS PRICING FOR $150 MILLION UNDERWRITTEN COMMON STOCK OFFERING
- Company Announcement: Trevi Therapeutics has announced a pricing of $150 million for its underwritten offering of common stock.
- Financial Strategy: The offering aims to raise capital to support the company's ongoing operations and development initiatives.
See More
Trevi Therapeutics Prices $150 Million Public Offering of Common Stock
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Arrangement: The offering is managed by top-tier firms including Morgan Stanley, Leerink Partners, Cantor, and Stifel, with Oppenheimer & Co. as the lead manager, indicating robust institutional support for the financing effort.
- Additional Share Option: Trevi has granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, a strategy that could further enhance the company's capital-raising capabilities and meet market demand.
- Expected Closing Date: The offering is anticipated to close around April 20, 2026, subject to customary closing conditions, and if successful, will provide critical funding for the company's ongoing research and market expansion efforts.
See More
Trevi Therapeutics Raises $150 Million in Public Offering
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market confidence in its investigational therapy Haduvio™.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering, indicating robust professional support in capital markets and enhancing investor trust in the company's future prospects.
- Additional Share Option: Trevi granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, providing flexibility that could further enhance the company's financing capabilities to support R&D and market expansion.
- Regulatory Compliance: The offering is conducted under a shelf registration statement on Form S-3 filed on November 13, 2025, ensuring compliance and providing transparent disclosures to investors, thereby strengthening market confidence in the company's governance.
See More
Trevi Therapeutics Announces $150M Public Offering
- Funding Size: Trevi Therapeutics has announced a public offering of $150 million aimed at supporting the development of Haduvio, its investigational therapy for chronic cough, indicating the company's proactive approach in drug development.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in shares, a strategy that not only provides extra financial flexibility but may also enhance market demand for its stock.
- R&D Focus: The proceeds will primarily support the development of Haduvio (oral nalbuphine ER), targeting chronic cough symptoms, which highlights Trevi Therapeutics' commitment to addressing this unmet medical need and potentially generating new revenue streams.
- Clinical Trial Plans: Trevi Therapeutics is set to conduct two pivotal Phase III trials focused on IPF-related chronic cough, having achieved alignment with the FDA, which lays a solid foundation for the company's future market access.
See More
Trevi Therapeutics to Participate in Multiple Healthcare Conferences
- Management Participation: Trevi Therapeutics' senior management will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, showcasing their research progress on chronic cough, which is expected to enhance investor interest in the company's R&D efforts.
- Key Event Schedule: The company will present its Haduvio™ therapy at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026, aiming to attract potential investors and strengthen market awareness.
- Investor Day Activities: Trevi plans to hold an Investor and Analyst Day on May 7, 2026, in New York, inviting key opinion leaders in chronic cough to enhance engagement and trust with investors.
- Chronic Cough Market Demand: Trevi's Haduvio™ addresses the urgent needs of approximately 150,000 U.S. patients with IPF and 230,000 with non-IPF ILD, highlighting its strategic significance in a market with high unmet medical needs.
See More
